Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for the Treatment of Large De Novo Coronary Lesions
Reviews in Cardiovascular Medicine · 12.10.2026 · 27 (10)
DOI: 10.31083/rcm50502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 12.10.2026. Verfasst von Wenjie Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, 100069 Beijing, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Healthcare Administration, First-Launch Project of Beijing Municipal Health Commission.
Abstract (Originalsprache)
Background
Although drug-coated balloons (DCBs) outperform drug-eluting stents (DESs) in the treatment of de novo small-vessel coronary lesions, no comparable studies are available for de novo large-vessel coronary lesions.
Methods
This retrospective study examined 960 patients with de novo large-vessel coronary lesions (reference vessel diameter ≥3.0 mm) who underwent paclitaxel DCB angioplasty or DES implantation at Beijing Anzhen Hospital. The study endpoints included all-cause death, myocardial infarction (MI), stroke, and target vessel revascularization (TVR). Kaplan–Meier (KM) curves and Cox regression analysis were used to investigate the clinical outcomes of patients in the DCB and DES groups.
Results
The overall incidence rates of major adverse cardiac and cerebrovascular events (MACCEs), all-cause death, MI, stroke, and TVR were 9.27% (89/960), 1.5% (14 patients), 0.9% (9 patients), 0.6% (6 patients), and 6.8% (65 patients), respectively. No significant differences were observed between the DCB and DES groups in MACCEs (13.2% vs. 5.6%; p = 0.511), all-cause death (1.9% vs. 1.0%; p = 0.763), MI (0.6% vs. 1.2%; p = 0.239), or stroke (0.6% vs. 0.6%; p = 0.361). However, the TVR rate was significantly higher in the DCB group than in the DES group (10.1% vs. 3.6%; p = 0.028), and this difference persisted after multivariate adjustment.
Conclusions
For patients with de novo lesions in target vessels with diameters ≥3.0 mm, the safety and efficacy of DCB therapy were comparable to those of DES therapy, except for target vessel revascularization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, 100069 Beijing, China.
- Department of Cardiology, Dong'e People's Hospital, 252299 Liaocheng, Shandong, China.
- Department of Cardiology, Langfang Fourth People's Hospital, 065700 Langfang, Hebei, China.
ORCID-Profile: Wenjie Wang, Hongfei Si, Lingjuan Li, Xiliang Zhao, Quan Li, Yong Zeng, Xianpeng Yu
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Healthcare Administration
- First-Launch Project of Beijing Municipal Health Commission
Zitieren
APA
Wang, W., Si, H., Li, L., Zhao, X., Li, Q., Zeng, Y., & Yu, X. (2026). Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for the Treatment of Large De Novo Coronary Lesions. Reviews in Cardiovascular Medicine, 27(10). https://doi.org/10.31083/rcm50502
Vancouver
Wang W, Si H, Li L, Zhao X, Li Q, Zeng Y, et al. Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for the Treatment of Large De Novo Coronary Lesions. Reviews in Cardiovascular Medicine. 2026;27(10). doi:10.31083/rcm50502
BibTeX
@article{Wang2026,
author = {Wang, Wenjie and Si, Hongfei and Li, Lingjuan and Zhao, Xiliang and Li, Quan and Zeng, Yong and Yu, Xianpeng},
title = {Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for the Treatment of Large De Novo Coronary Lesions},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
volume = {27},
number = {10},
doi = {10.31083/rcm50502}
}
EUVIMED